EVER-206
- Generic Name
- EVER-206
Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 34
- Registration Number
- NCT04868292
- Locations
- 🇬🇧
Medical Facility, Manchester, United Kingdom
Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT04865393
- Locations
- 🇳🇿
Medical Facility, Christchurch, New Zealand
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 94
- Registration Number
- NCT03792308
- Locations
- 🇦🇺
Scientia Clinical Research Ltd., Randwick, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath